Clinical trials: Primary Immune Thrombocytopenia (ITP)
Primary Immune Thrombocytopenia (ITP)
A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
A randomized, double-blind, placebo-controlled design was designed to evaluate the safety and tolerability, pharmacokinetic/pharmacodynamic profile, and immunogenicity of multiple administration of STSA-1301 subcutaneous…
- Trial name
- NCT06929299
- Testing
- STSA-1301 subcutaneous injection
- Where
- 7 sites in China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangsu BioJeTay Biotechnology Co., Ltd.
Primary Immune Thrombocytopenia (ITP)
Study of Immune Thrombocytopenia Pathogenesis:
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet count responsible for bleedings. The disease is mostly mediated by antiplatelet antibodies produced by specific B cells.
- Trial name
- PTI PARI (NCT02042560)
- Testing
- Blood samples, Spleen samples
- Where
- 3 sites in France
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon